CY1119448T1 - N-(5S,6S,9R)-5-AMlNO-6-(2,3-ΔΙΦΘOPOΦAINYΛ)-6,7,8,9-TETPAΫΔPO-5H-ΚΥΚΛΟΕΠΤΑ[Β]ΠΥΡΙΔΙΝ-9-ΥΛ-4-(2-ΟΞΟ-2, 3-ΔΙΫΔΡΟ-1Η-ΙΜΙΔΑΖΟ[4,5-Β] ΠΥΡΙΔΙΝ-1-ΥΛ)ΠΙΠΕΡΙΔΙΝΟ-1-ΚΑΡΒΟΞΥΛΙΚΟ, ΗΜΙ-ΘΕΙΙΚΟ ΑΛΑΣ - Google Patents
N-(5S,6S,9R)-5-AMlNO-6-(2,3-ΔΙΦΘOPOΦAINYΛ)-6,7,8,9-TETPAΫΔPO-5H-ΚΥΚΛΟΕΠΤΑ[Β]ΠΥΡΙΔΙΝ-9-ΥΛ-4-(2-ΟΞΟ-2, 3-ΔΙΫΔΡΟ-1Η-ΙΜΙΔΑΖΟ[4,5-Β] ΠΥΡΙΔΙΝ-1-ΥΛ)ΠΙΠΕΡΙΔΙΝΟ-1-ΚΑΡΒΟΞΥΛΙΚΟ, ΗΜΙ-ΘΕΙΙΚΟ ΑΛΑΣInfo
- Publication number
- CY1119448T1 CY1119448T1 CY20171101052T CY171101052T CY1119448T1 CY 1119448 T1 CY1119448 T1 CY 1119448T1 CY 20171101052 T CY20171101052 T CY 20171101052T CY 171101052 T CY171101052 T CY 171101052T CY 1119448 T1 CY1119448 T1 CY 1119448T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pyridin
- sulfate
- semi
- compound
- inflammation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Αποκαλύπτεται ημιθειικό άλας της Ένωσης (I): και κρυσταλλικές μορφές του ημιθειικού άλατος. Επίσης αποκαλύπτονται μέθοδοι χρήσης του ημιθειικού άλατος της Ένωσης (I) ως ανταγωνιστή υποδοχέα CGRP και φαρμακευτικών συνθέσεων που περιλαμβάνουν το ημιθειικό άλας της Ένωσης (I). Το ημιθειικό άλας της Ένωσης (I) είναι χρήσιμο στην θεραπεία, αποτροπή ή ανακούφιση διαταραχών που συμπεριλαμβάνουν ημικρανία και άλλες κεφαλαλγίες, νευρογενή αγγειοδιαστολή, νευρογενή φλεγμονή, θερμική βλάβη, κυκλοφορικό σοκ, έξαψη που σχετίζεται με εμμηνόπαυση, φλεγμονώδεις ασθένειες της αναπνευστικής οδού, όπως άσθμα και χρόνια αποφρακτική πνευμονοπάθεια(COPD).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261603598P | 2012-02-27 | 2012-02-27 | |
PCT/US2013/027648 WO2013130402A1 (en) | 2012-02-27 | 2013-02-25 | N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119448T1 true CY1119448T1 (el) | 2018-03-07 |
Family
ID=47844498
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171101052T CY1119448T1 (el) | 2012-02-27 | 2017-10-10 | N-(5S,6S,9R)-5-AMlNO-6-(2,3-ΔΙΦΘOPOΦAINYΛ)-6,7,8,9-TETPAΫΔPO-5H-ΚΥΚΛΟΕΠΤΑ[Β]ΠΥΡΙΔΙΝ-9-ΥΛ-4-(2-ΟΞΟ-2, 3-ΔΙΫΔΡΟ-1Η-ΙΜΙΔΑΖΟ[4,5-Β] ΠΥΡΙΔΙΝ-1-ΥΛ)ΠΙΠΕΡΙΔΙΝΟ-1-ΚΑΡΒΟΞΥΛΙΚΟ, ΗΜΙ-ΘΕΙΙΚΟ ΑΛΑΣ |
CY20191100951T CY1122121T1 (el) | 2012-02-27 | 2019-09-11 | N-(5s,6s,9r)-5-amino-6-(2,3-διφθοpoφainyλ)-6,7,8,9-tetpaϋδpo-5h-κυκλοεπτα[β]πυριδιν-9-υλ-4-(2-οξο-2, 3-διϋδρο-1η-ιμιδαζο[4,5-β]πυριδιν-1-υλ)πιπεριδινο-1-καρβοξυλικο αλας |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100951T CY1122121T1 (el) | 2012-02-27 | 2019-09-11 | N-(5s,6s,9r)-5-amino-6-(2,3-διφθοpoφainyλ)-6,7,8,9-tetpaϋδpo-5h-κυκλοεπτα[β]πυριδιν-9-υλ-4-(2-οξο-2, 3-διϋδρο-1η-ιμιδαζο[4,5-β]πυριδιν-1-υλ)πιπεριδινο-1-καρβοξυλικο αλας |
Country Status (25)
Country | Link |
---|---|
US (1) | US8759372B2 (el) |
EP (2) | EP3254681B1 (el) |
JP (2) | JP6208154B2 (el) |
KR (2) | KR102220969B1 (el) |
CN (1) | CN104136437B (el) |
AU (1) | AU2013226361B2 (el) |
BR (1) | BR112014021032B1 (el) |
CA (1) | CA2865585C (el) |
CY (2) | CY1119448T1 (el) |
DK (2) | DK3254681T3 (el) |
EA (1) | EA025358B1 (el) |
ES (2) | ES2642737T3 (el) |
HK (1) | HK1248111B (el) |
HR (2) | HRP20171620T1 (el) |
HU (2) | HUE034936T2 (el) |
IL (1) | IL234272B (el) |
LT (2) | LT2820016T (el) |
MX (1) | MX352171B (el) |
NO (1) | NO2935439T3 (el) |
PL (2) | PL2820016T3 (el) |
PT (2) | PT3254681T (el) |
RS (2) | RS56556B1 (el) |
SG (1) | SG11201404834XA (el) |
SI (2) | SI2820016T1 (el) |
WO (1) | WO2013130402A1 (el) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101855242B1 (ko) | 2012-01-26 | 2018-05-09 | 크리스토퍼 제이. 소레스 | 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도 |
JP6208154B2 (ja) * | 2012-02-27 | 2017-10-04 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | N−(5S,6S,9R)−5−アミノ−6−(2,3−ジフルオロフェニル)−6,7,8,9−テトラヒドロ−5H−シクロヘプタ[b]ピリジン−9−イル−4−(2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−b]ピリジン−1−イル)ピペリジン−1−カルボキシレート塩 |
EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
CA2978085C (en) | 2015-03-06 | 2023-01-17 | Atea Pharmaceuticals, Inc. | .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
US11390654B2 (en) * | 2016-09-02 | 2022-07-19 | Christopher Joseph Soares | Use of CGRP receptor antagonists in neuroprotection and neurological disorders |
CN116036114A (zh) | 2016-09-07 | 2023-05-02 | 阿堤亚制药公司 | 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸 |
JP7066728B2 (ja) * | 2017-02-01 | 2022-05-13 | アテア ファーマシューティカルズ, インコーポレイテッド | C型肝炎ウイルスの治療のためのヌクレオチドヘミ硫酸塩 |
US20210000814A1 (en) * | 2018-03-25 | 2021-01-07 | Biohaven Pharmaceutical Holding Company Ltd. | Rimegepant for cgrp related disorders |
EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
MX2021008191A (es) * | 2019-01-20 | 2021-08-11 | Biohaven Pharm Holding Co Ltd | Antagonistas del péptido relacionado con el gen de calcitonina (cgrp) para el tratamiento de la irrupción de migraña. |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
AU2022230300A1 (en) | 2021-03-02 | 2023-09-21 | Cgrp Diagnostics Gmbh | Treatment and/or reduction of occurrence of migraine |
WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
WO2023034466A1 (en) * | 2021-09-02 | 2023-03-09 | Pfizer Ireland Pharmaceuticals | Cgrp antagonists for treating psoriasis |
CN115850266A (zh) * | 2021-09-26 | 2023-03-28 | 奥锐特药业(天津)有限公司 | 瑞美吉泮新晶型及其制备方法 |
CN116554164A (zh) * | 2022-01-27 | 2023-08-08 | 奥锐特药业(天津)有限公司 | 一种瑞美吉泮的制备方法 |
WO2023175632A1 (en) * | 2022-03-17 | 2023-09-21 | Msn Laboratories Private Limited, R&D Center | Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA24500A1 (fr) * | 1997-03-21 | 1998-10-01 | Lg Life Sciences Ltd | Derive du sel d'acide carboxylique de naphthyridine . |
JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
JPWO2005085228A1 (ja) | 2004-03-05 | 2008-01-17 | 萬有製薬株式会社 | シクロアルカノピリジン誘導体 |
MX2007004393A (es) | 2004-10-13 | 2007-04-25 | Merck & Co Inc | Antagonistas del receptor a peptido relacionado con el gen calcitonina. |
WO2006047196A2 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | Cgrp receptor antagonists |
CN101421267B (zh) | 2006-04-10 | 2011-10-19 | 默沙东公司 | 制备吡啶杂环cgrp拮抗剂中间体的方法 |
DE102006017827A1 (de) * | 2006-04-13 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue kristalline Verbindungen |
US8143403B2 (en) | 2008-04-11 | 2012-03-27 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
US8314117B2 (en) * | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
US8669368B2 (en) | 2010-10-12 | 2014-03-11 | Bristol-Myers Squibb Company | Process for the preparation of cycloheptapyridine CGRP receptor antagonists |
US8748429B2 (en) | 2011-04-12 | 2014-06-10 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
JP6208154B2 (ja) * | 2012-02-27 | 2017-10-04 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | N−(5S,6S,9R)−5−アミノ−6−(2,3−ジフルオロフェニル)−6,7,8,9−テトラヒドロ−5H−シクロヘプタ[b]ピリジン−9−イル−4−(2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−b]ピリジン−1−イル)ピペリジン−1−カルボキシレート塩 |
-
2013
- 2013-02-25 JP JP2014558927A patent/JP6208154B2/ja active Active
- 2013-02-25 PT PT171805872T patent/PT3254681T/pt unknown
- 2013-02-25 CN CN201380011305.6A patent/CN104136437B/zh active Active
- 2013-02-25 KR KR1020207003401A patent/KR102220969B1/ko active IP Right Grant
- 2013-02-25 BR BR112014021032-2A patent/BR112014021032B1/pt active IP Right Grant
- 2013-02-25 WO PCT/US2013/027648 patent/WO2013130402A1/en active Application Filing
- 2013-02-25 SI SI201330759T patent/SI2820016T1/sl unknown
- 2013-02-25 PT PT137086039T patent/PT2820016T/pt unknown
- 2013-02-25 DK DK17180587.2T patent/DK3254681T3/da active
- 2013-02-25 US US13/775,528 patent/US8759372B2/en active Active
- 2013-02-25 RS RS20171092A patent/RS56556B1/sr unknown
- 2013-02-25 AU AU2013226361A patent/AU2013226361B2/en active Active
- 2013-02-25 SG SG11201404834XA patent/SG11201404834XA/en unknown
- 2013-02-25 LT LTEP13708603.9T patent/LT2820016T/lt unknown
- 2013-02-25 EP EP17180587.2A patent/EP3254681B1/en active Active
- 2013-02-25 ES ES13708603.9T patent/ES2642737T3/es active Active
- 2013-02-25 HU HUE13708603A patent/HUE034936T2/hu unknown
- 2013-02-25 EA EA201491585A patent/EA025358B1/ru not_active IP Right Cessation
- 2013-02-25 KR KR1020147023856A patent/KR102076118B1/ko active IP Right Grant
- 2013-02-25 CA CA2865585A patent/CA2865585C/en active Active
- 2013-02-25 ES ES17180587T patent/ES2746031T3/es active Active
- 2013-02-25 LT LTEP17180587.2T patent/LT3254681T/lt unknown
- 2013-02-25 HU HUE17180587A patent/HUE047050T2/hu unknown
- 2013-02-25 PL PL13708603T patent/PL2820016T3/pl unknown
- 2013-02-25 PL PL17180587T patent/PL3254681T3/pl unknown
- 2013-02-25 SI SI201331560T patent/SI3254681T1/sl unknown
- 2013-02-25 MX MX2014009544A patent/MX352171B/es active IP Right Grant
- 2013-02-25 DK DK13708603.9T patent/DK2820016T3/da active
- 2013-02-25 RS RSP20191191 patent/RS59295B1/sr unknown
- 2013-02-25 EP EP13708603.9A patent/EP2820016B1/en active Active
- 2013-12-10 NO NO13811338A patent/NO2935439T3/no unknown
-
2014
- 2014-08-24 IL IL234272A patent/IL234272B/en active IP Right Grant
-
2017
- 2017-09-06 JP JP2017171358A patent/JP6476253B2/ja active Active
- 2017-10-10 CY CY20171101052T patent/CY1119448T1/el unknown
- 2017-10-25 HR HRP20171620TT patent/HRP20171620T1/hr unknown
-
2018
- 2018-06-12 HK HK18107632.9A patent/HK1248111B/zh unknown
-
2019
- 2019-09-11 CY CY20191100951T patent/CY1122121T1/el unknown
- 2019-09-16 HR HRP20191655 patent/HRP20191655T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119448T1 (el) | N-(5S,6S,9R)-5-AMlNO-6-(2,3-ΔΙΦΘOPOΦAINYΛ)-6,7,8,9-TETPAΫΔPO-5H-ΚΥΚΛΟΕΠΤΑ[Β]ΠΥΡΙΔΙΝ-9-ΥΛ-4-(2-ΟΞΟ-2, 3-ΔΙΫΔΡΟ-1Η-ΙΜΙΔΑΖΟ[4,5-Β] ΠΥΡΙΔΙΝ-1-ΥΛ)ΠΙΠΕΡΙΔΙΝΟ-1-ΚΑΡΒΟΞΥΛΙΚΟ, ΗΜΙ-ΘΕΙΙΚΟ ΑΛΑΣ | |
CY1123637T1 (el) | Αναστολεις μεθυλοτρανσφερασης αργινινης και χρησεις αυτων | |
PH12017500146A1 (en) | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof | |
CO2018002829A2 (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) | |
TN2012000139A1 (en) | Cgrp receptor antagonists | |
TN2015000005A1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
PH12014502789A1 (en) | N-alkyltriazole compounds as lpar antagonists | |
EA201490859A1 (ru) | Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона | |
WO2009126530A3 (en) | Piperidine derivatives as cgrp receptor antagonists | |
WO2014155300A3 (en) | Substitued pyrimidine amine derivatives as tak-1 inhibitors | |
MX2014014711A (es) | Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar). | |
EA201391239A1 (ru) | Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ | |
BR112015014701B8 (pt) | Derivados de benzimidazol e seus usos | |
PH12015501339A1 (en) | Indole carboxamide derivatives as p2x7 receptor antagonists | |
MX2013008431A (es) | Antagonista del receptor de mineralocorticoides. | |
MX2013008296A (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
UA107353C2 (en) | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | |
UA109867C2 (ru) | Замещенные соединения пиразола как антагонисты рецепторов лизофосфатидной кислоты (lpar) | |
TN2013000420A1 (en) | 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors | |
MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
CL2017002605A1 (es) | Derivados de indol | |
WO2014147636A8 (en) | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists | |
CY1114902T1 (el) | Ανταγωνιστες cgrp υποδοχεα | |
UA111851C2 (uk) | Сполуки піридазинону та їх використання як інгібіторів daao |